Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03%
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dermatitis, Atopic
Conditions
Dermatitis, Atopic
Trial Timeline
Apr 1, 2003 → Dec 1, 2004
NCT ID
NCT00535691About Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03%
Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03% is a phase 2 stage product being developed by Astellas Pharma for Dermatitis, Atopic. The current trial status is completed. This product is registered under clinical trial identifier NCT00535691. Target conditions include Dermatitis, Atopic.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00535691 | Phase 2 | Completed |
Competing Products
20 competing products in Dermatitis, Atopic